$IDXG News

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners

Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results

Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting

Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

Interpace Diagnostics Strategic Stock Exchange for Nasdaq Uplisting

Interpace Biosciences GAAP EPS of $0.48, revenue of $12M

Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

Interpace Diagnostics? Announces Undefined Extension of Medicare Coverage for PancraGEN?, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

Interpace Biosciences announces extension of Medicare coverage for PancraGEN

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

Interpace Biosciences Appoints Tom Freeburg As CFO